Citi lowered the firm’s price target on Illumina (ILMN) to $85 from $90 and keeps a Neutral rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes tariffs and the National Institutes of Health spending cuts are overhands on the sector.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Argus cuts Illumina target, sees buying opportunity
- Illumina price target lowered to $122 from $150 at Guggenheim
- Corvex’s Keith Meister to join Illumina’s board, WSJ reports
- Illumina elects Dr. Scott Gottlieb as Chair, Keith Meister to join board
- No change to Illumina story amid board changes, ‘eventful’ 24 hours, says BofA